Dr. Nigg’s research focuses on the underlying mechanisms and causes in attention deficit hyperactivity disorder (ADHD) across the lifespan. The primary focus is on cognitive and neuropsychological mechanisms. However, studies of genetics, family dynamics, personality and temperament, environmental toxins, and neuroimaging of ADHD are also ongoing.
Joel Nigg
Director, Division of Psychology
Oregon Health and Science University
From this contributor
Insights for autism from attention deficit hyperactivity disorder
Autism and attention deficit hyperactivity disorder show genetic and neurobiological overlap, which may provide clues to the origin of both disorders, says Joel Nigg.
Insights for autism from attention deficit hyperactivity disorder
By
Joel Nigg
7 February 2012 | 8 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read